Shanghai Haohai Biological Technology Resultados de beneficios anteriores
Pasado controles de criterios 4/6
Los beneficios de Shanghai Haohai Biological Technology han disminuido a una tasa media anual de -4.5%, mientras que en la industria Biotechs los beneficios crecieron en un 11.7% anualmente. Los ingresos han ido creciendo a una tasa media de 12.5% al año. La rentabilidad financiera de Shanghai Haohai Biological Technology es de 6.9%, y sus márgenes netos son de 15.8%.
Información clave
-0.8%
Tasa de crecimiento de los beneficios
-2.1%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 11.0% |
| Tasa de crecimiento de los ingresos | 14.0% |
| Rentabilidad financiera | 6.9% |
| Margen neto | 16.1% |
| Última actualización de beneficios | 31 Mar 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All
May 22
Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Apr 17Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?
Feb 12Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Nov 14Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 28We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Mar 09These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Nov 25Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet
Jul 30Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price
May 08Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?
Apr 19Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Mar 04Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Mar 03Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?
Jan 10Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly
Oct 08Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly
Jul 07Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%
May 27These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well
Apr 04Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%
Mar 16Can Mixed Fundamentals Have A Negative Impact on Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Current Share Price Momentum?
Feb 23What Type Of Shareholders Own The Most Number of Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Shares?
Feb 05
Does Shanghai Haohai Biological Technology's (HKG:6826) Statutory Profit Adequately Reflect Its Underlying Profit?
Jan 21Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Should Think About This Before Buying It For Its Dividend
Jan 06We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt
Dec 22Desglose de ingresos y gastos
Cómo gana y gasta dinero Shanghai Haohai Biological Technology. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 24 | 2,689 | 432 | 1,211 | 231 |
| 31 Dec 23 | 2,654 | 416 | 1,223 | 220 |
| 30 Sep 23 | 2,503 | 346 | 1,194 | 215 |
| 30 Jun 23 | 2,453 | 315 | 1,176 | 207 |
| 31 Mar 23 | 2,278 | 248 | 1,131 | 195 |
| 31 Dec 22 | 2,130 | 180 | 1,088 | 182 |
| 30 Sep 22 | 2,063 | 203 | 1,132 | 175 |
| 30 Jun 22 | 1,861 | 192 | 1,065 | 171 |
| 31 Mar 22 | 1,805 | 272 | 982 | 169 |
| 31 Dec 21 | 1,750 | 352 | 898 | 168 |
| 30 Sep 21 | 1,702 | 428 | 759 | 156 |
| 30 Jun 21 | 1,674 | 434 | 733 | 143 |
| 31 Mar 21 | 1,594 | 370 | 793 | 135 |
| 31 Dec 20 | 1,324 | 230 | 772 | 126 |
| 30 Sep 20 | 1,343 | 232 | 854 | 121 |
| 30 Jun 20 | 1,306 | 216 | 859 | 121 |
| 31 Mar 20 | 1,437 | 279 | 831 | 120 |
| 31 Dec 19 | 1,595 | 371 | 813 | 116 |
| 30 Sep 19 | 1,537 | 353 | 759 | 108 |
| 30 Jun 19 | 1,570 | 386 | 732 | 108 |
| 31 Mar 19 | 1,478 | 375 | 699 | 100 |
| 31 Dec 18 | 1,546 | 415 | 737 | 95 |
| 30 Sep 18 | 1,523 | 411 | 715 | 89 |
| 30 Jun 18 | 1,501 | 408 | 692 | 83 |
| 31 Mar 18 | 1,423 | 390 | 650 | 80 |
| 31 Dec 17 | 1,345 | 372 | 609 | 76 |
| 30 Sep 17 | 1,214 | 351 | 555 | 67 |
| 30 Jun 17 | 1,083 | 329 | 502 | 59 |
| 31 Mar 17 | 967 | 317 | 440 | 53 |
| 31 Dec 16 | 851 | 305 | 378 | 47 |
| 30 Sep 16 | 787 | 295 | 358 | 44 |
| 30 Jun 16 | 724 | 284 | 337 | 40 |
| 31 Mar 16 | 694 | 279 | 319 | 38 |
| 31 Dec 15 | 664 | 273 | 301 | 35 |
| 30 Sep 15 | 630 | 258 | 278 | 32 |
| 30 Jun 15 | 597 | 243 | 255 | 28 |
| 31 Mar 15 | 556 | 213 | 246 | 27 |
| 31 Dec 14 | 516 | 184 | 236 | 26 |
| 30 Sep 14 | 482 | 169 | 221 | 27 |
| 30 Jun 14 | 449 | 154 | 206 | 28 |
| 31 Mar 14 | 425 | 148 | 192 | 26 |
| 31 Dec 13 | 401 | 142 | 178 | 24 |
Ingresos de calidad: 6826 tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (15.8%) de 6826 son superiores a los del año pasado (8.6%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de 6826 han disminuido en un 4.5% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de 6826 en el último año (130.6%) supera su media de 5 años (-4.5% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de 6826 en el último año (130.6%) superó al de la industria Biotechs 22.1%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de 6826 (6.9%) se considera baja.